| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| nabiximols | arylalkylamine n-acetyltransferase | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | acetyl-coa acetyltransferase, mitochondrial | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | voltage-dependent t-type calcium channel subunit alpha-1g | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | voltage-dependent t-type calcium channel subunit alpha-1h | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | voltage-dependent t-type calcium channel subunit alpha-1i | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | catalase | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | neuronal acetylcholine receptor subunit alpha-7 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | cannabinoid receptor 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | cannabinoid receptor 2 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | quinone oxidoreductase | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | steroid 17-alpha-hydroxylase/17,20 lyase | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | cytochrome p450 1a1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | cytochrome p450 1a2 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | cytochrome p450 1b1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | cytochrome p450 2d6 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | substrate,inhibitor |
| nabiximols | cytochrome p450 3a5 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | cytochrome p450 3a7 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | fatty-acid amide hydrolase 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor,inducer |
| nabiximols | glycine receptor subunit alpha-1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | glycine receptor (alpha-1/beta) | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | glycine receptor subunit alpha-3 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | glycine receptor (alpha-1/beta) | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | g-protein coupled receptor 12 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inverse agonist |
| nabiximols | n-arachidonyl glycine receptor | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | g-protein coupled receptor 55 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | glutathione peroxidase 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | stimulator |
| nabiximols | glutathione reductase, mitochondrial | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | stimulator |
| nabiximols | 3-hydroxy-3-methylglutaryl-coenzyme a reductase | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | stimulator |
| nabiximols | 5-hydroxytryptamine receptor 1a | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | 5-hydroxytryptamine receptor 2a | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | indoleamine 2,3-dioxygenase 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | n-acylethanolamine-hydrolyzing acid amidase | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | delta-type opioid receptor | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | mu-type opioid receptor | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | peroxisome proliferator-activated receptor gamma | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | prostaglandin g/h synthase 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | prostaglandin g/h synthase 2 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | superoxide dismutase [cu-zn] | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | inhibitor |
| nabiximols | transient receptor potential cation channel subfamily a member 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | transient receptor potential cation channel subfamily m member 8 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | transient receptor potential cation channel subfamily v member 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | transient receptor potential cation channel subfamily v member 2 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | transient receptor potential cation channel subfamily v member 3 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | transient receptor potential cation channel subfamily v member 4 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| nabiximols | voltage-dependent anion-selective channel protein 1 | small molecule | NA | drugbank | Malignant Neoplasms[MeSHID:D009369] Disease[MeSHID:D004194] Multiple Sclerosis[MeSHID:D009103] Neuralgia[MeSHID:D009437] Compliance behavior[MeSHID:D010349] Muscle Spasticity[MeSHID:D009128] Pain[MeSHID:D010146] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Spasm[MeSHID:D013035] |
NA | investigational | unknown |
| click here to return to the previous page | ||||||||